Risperidone and olanzapine: Optimal dosing for efficacy and tolerability in patients with schizophrenia

International Clinical Psychopharmacology

Volumn 13, Issue 6, 1998, Pages 253-262

  Kasper, Siegfried ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Clinical trial; Dose; Efficacy; Extrapyramidal symptoms; Olanzapine; Risperidone; Schizophrenia

Indexed keywords

OLANZAPINE; RISPERIDONE;

ARTICLE; CLINICAL TRIAL; CONSTIPATION; DOSE CALCULATION; DRUG EFFICACY; DRUG INFORMATION; DRUG TOLERABILITY; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MARKETING; META ANALYSIS; NAUSEA; ORTHOSTATIC HYPOTENSION; PERSONALITY DISORDER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RHINITIS; SCHIZOPHRENIA; SOMNOLENCE; TACHYCARDIA; VERTIGO; WEIGHT GAIN;

EID: 0031795951     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199811000-00003     Document Type: Article

References (51)

1. Addington DE, Jones B, Bloom D, Chouinard G, Remington G, Albright P (1993): Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 15:917-926.
2. Albright PS, Livingstone S, Keegan DL, Ingham M, Shrikhande S, Le Lorier J (1996): Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy: a retrospective analysis using the Saskatchewan Health linkable databases. Clin Drug Invest 11:289-299.
3. Andreasen NC (1995): Symptoms, signs, and diagnosis of schizophrenia. Lancet 346:477-481.
4. Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S, et al. (1996): Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14:111-123.
5. Beasely CM (1997): Safety of olanzapine. J Clin Psychiatry 15:19-21.
6. Beasley CM, Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PV, et al. (1997a): Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 7:125-137.
7. Beasley CM, Tollefson GD, Tran PV (1997b): Safety of olanzapine. J Clin Psychiatry 58:13-17.
8. Bleich A, Brown SL, Kahn R, van Praag HM (1988): The role of serotonin in schizophrenia. Schizophr Bull 14:297-315.
9. Borison RL (1997): Recent advances in the pharmacotherapy of schizophrenia. Harvard Rev Psychiatry 4:255-271.
10. Breier A, Schreiber JL, Dyer J, Pickar D (1991): National Institute of Mental health: longitudinal study of chronic schizophrenia. Arch Gen Psychiatry 48:239-246.
11. Carlsson A (1995): Neurocircuitries and neurotransmitter interactions in schizophrenia. Int Clin Psychopharmacol 10:21-28.
12. Carlsson A, Lindquist J (1963): Effect of chlorpromazine and haloperidol on formation of 3-methoxytyranine and normetanephrine in mouse brain. Acta Pharm Toxicol 20:140-144.
13. Casey DE (1987): Tardive dyskinesia. In: Psychopharmacology: the third generation of progress. (H Meltzer, ed.), New York: Raven Press, pp. 1411-1419.
14. Casey DE, Keepers GA (1988): Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia. In: Psychopharmacology: current trends (DE, A Vibeke Christensen, eds), Berlin: Springer, pp. 74-93.
15. Casey DE (1991): Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 10:21-28.
16. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. (1993): A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13:25-40.
17. Crow TJ (1985): The two-syndrome concept: origins and status. Schizophrenia Bull 11:471-486.
18. Cunningham Owens DG (1996): Advances in psychopharmacology - schizophrenia. Br Med Bull 52:556-574.
19. de Leon J, Simpson G (1991): Do schizophrenic negative symptoms respond to neuroleptics? Int Psych 7:39-47.
20. Eaton WW, Thara R, Federman B, Melton B, Liang K-Y (1995): Structure and course of positive and negative symptoms in schizophrenia. Arch Gen Psychiatry 52:127-134.
21. Gheuens J, Grebb JA (1998): Comments on article by Tran and colleagues, 'Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders'. J Clin Psychopharm 18:176-177.
22. Goff DC (1995): Have the serotonin-dopamine antagonists rendered traditional antipsychotic agents obsolete? Harvard Rev Psychiatry 3:101-103.
23. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G (1994): One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 151, 1409-1416.
24. Janicak PG, Davis JM (1996): Antipsychotic dosing strategies in acute schizophrenia. Int Clin Psychopharmacol 11:35-40.
25. Kane JM (1987): Treatment of schizophrenia. Schizophr Bull 13:133-156.
26. Kasper S, Küfferle B (1998): Comments on article by Tran and colleagues, 'Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders'. J Clin Psychopharmacol in press
27. Kasper S, Tauscher J, Küfferle B, Heßelmann B, Barnas C, Brücke T (1998): IBZM-SPECT imaging of dopamine-2 receptors with typical and atypical neuroleptics. Eur Psychiatry 13 (Suppl. 1):9S-14S.
28. Kleinberg DL, Brecher M, Davis JM (1998): Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol in press.
29. 2 dopamine receptor occupancy: different profiles with atypical neuroleptics [abstract]. Eur Neuropsychopharm 5:337.
30. 2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics. Am J Psychiatry 153:183-190.
31. Marder SR, Meibach RC (1994): Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825-835.
32. Marder SR, Davis JM, Chouinard G (1997): The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 58:538-546.
33. Möller HJ (1993): Neuroleptic treatment of negative symptoms in schizophrenic patients: efficacy problems and methodological difficulties. Eur Neuropsychopharmacol 3:1-11.
34. National Disease Therapeutic Index (NDTI) (1997): International Medical Statistics (IMS) America full year 1997 data.
35. 2 receptor occupancy studies and clinical response. Br J Psychiatry 168 (Suppl. 29):40-44.
36. Peuskens J and the Risperidone Study Group (1995): Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 166:712-726.
37. Pickar D (1995): Prospects for pharmacotherapy of schizophrenia. Lancet 245:557-562.
38. Regier DA, Boyd JH, Burke JD, Rae DS, Myers JK, Kramer M, et al. (1988): One-month prevalence of mental disorders in the United States. Based on five epidemiologic catchment area sites. Arch Gen Psychiatry 45:977-986.
39. Reyntjens A, Gelders YG, Hoppenbrouwers M-LJA, Vanden Bussche G (1986): Thymosthenic effects of ritanserin (R55667), a centrally acting serotonin-S2 receptor blocker. Drug Development Res 8:205-211.
40. Risperdal (Risperidone) (1998): The Physicians' Desk Reference, 52nd ed. Medical Economics Data Production Company, Montvale, New Jersey, USA.
41. Schooler NJ (1998): Comments on article by Tran and colleagues. 'Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders'. J Clin Psychopharm 18:174-175.
42. Simpson GM, Lindenmayer JP (1997): Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol 17:194-201.
43. Strauss JS, Carpenter WT, Bartko JJ (1974): The diagnosis and understanding of schizophrenia, part III: speculations on the processes that underlie schizophrenic symptoms and signs. Schizophr Bull 11:61-79.
44. Tarsy D (1983): Neuroleptic-induced extrapyramidal reactions: classification, description, and diagnosis. Clin Neuropharmacol 6: S9-S26.
45. Tauscher J, Küfferle B, Barnas C, Asenbaum S, Brücke T, Kasper S (1997): Visualisation of dopamine-2 receptor occupancy in psychotic patients treated with olanzapine, risperidone, clozapine and haloperidol. Eur Neuropsychopharmacol 7:S219.
46. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, et al. (1997): Olanzapine versus haloperidol in the treatment of schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154:457-465.
47. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley CB, et al. (1997): Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 17:408-417.
48. Tuma AH, May PRA (1979): And if that doesn't work, what next? A study of treatment failures in schizophrenia. J Nerv Ment Dis 167:566-571.
49. Weiden PJ, Shaw E, Mann JJ (1986): Causes of neuroleptic noncompliance. Psychiatric Annals 16:571-575.
50. Wooley DW, Shaw E (1954): A biochemical and pharmacological suggestion about certain mental disorders. Proc Natl Acad Sci USA 40:228-231.
51. Zyprexa (olanzapine) (1998): The Physicians' Desk Reference, 52nd ed. Medical Economics Data Production Company, Montvale, New Jersey, USA.